Compare Sana Biotechnology Inc (SANA) vs Ermenegildo Zegna N.V. Ordinary Shares (ZGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Ermenegildo Zegna N.V. Ordinary Shares — how do they compare? Sana Biotechnology Inc trades at $2.34 (market cap $719.96M), while Ermenegildo Zegna N.V. Ordinary Shares trades at $12.8 (market cap $3.48B). The key difference: Ermenegildo Zegna N.V. Ordinary Shares is far larger — about 4.8× Sana Biotechnology Inc's market cap, and Ermenegildo Zegna N.V. Ordinary Shares pays a 1.06% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 24 Days and Ermenegildo Zegna N.V. Ordinary Shares for 0 Days on average.
| SANA | ZGN | |
|---|---|---|
Market Cap | $719.96M | $3.48B |
Volume | 4,901,517 | 1,076,161 |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $15.25 |
52-Week Low | $2.33 | $8.69 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $633.21M | $4.43B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.41, down 8.02% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company shows no revenue with substantial losses (-$244.17M net income in 2025) and negative cash flow, though analyst consensus remains strongly positive with 82% buy ratings. Recent investor conference presentations indicate active business development efforts.
The stock presents high-risk speculative potential with strong Wall Street support but faces fundamental challenges including no revenue generation and significant cash burn. Investment opportunity hinges on successful clinical developments, while risks include continued operational losses and potential dilution from financing activities.
ZGN trades at $12.94, up 2.7% with a neutral technical outlook. The stock shows mixed fundamentals with a high P/E of 38.5 but strong gross margins of 67.58%. Recent earnings beat expectations in three of the last four quarters, though Q2 2026 missed estimates. Analyst consensus is bullish with a $14.12 price target and 66.7% buy ratings. Revenue growth continues with 2025 reaching $1.92B, though net margins compressed to 3.98%.
ZGN presents a growth opportunity with expanding DTC momentum and margin potential, but faces valuation concerns and competitive pressures. The stock's upside depends on sustained earnings growth and successful execution of the retail-first strategy amidst fashion sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Ermenegildo Zegna N.V. Ordinary Shares
Ermenegildo Zegna N.V. is a luxury fashion group whose brands include Zegna, Thom Browne, and Tom Ford Fashion. The company operates a vertically integrated supply chain, sourcing wool from its own Australian farm through to finished garment production.
Read more on ZGN →
